Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
When it comes to treating locally advanced rectal cancer, shorter isn't necessarily worse. A large national study found that patients who received just 5 days of radiation had nearly identical survival rates to those who underwent 4–6 weeks of treatment. The main difference? Long-course radiation was better at shrinking lymph nodes, but the clinical significance of that gap remains unclear.
For patients with locally advanced rectal cancer undergoing total neoadjuvant therapy (chemo + radiation before surgery), a major question has been: does the length of radiation treatment actually matter? A new study published in Diseases of the Colon & Rectum suggests the answer is largely no — at least when it comes to survival.
Researchers analyzed data from over 12,000 patients in the National Cancer Database and compared outcomes between those who received short-course radiation (5 days, no radiosensitizing chemo) and long-course radiation (4–6 weeks, with radiosensitizing chemo). After carefully matching the groups, survival rates at 48 months were nearly identical — 89.6% vs. 90.5% — with no significant differences in metastasis rates, complete response rates, or surgical margins.
The one notable edge for long-course treatment: better nodal downstaging (66.5% vs. 62.7%). Meanwhile, short-course patients were more likely to undergo sphincter-preserving surgery, which can meaningfully impact quality of life.
Key Takeaways:
Why it matters: These findings give clinicians and patients more flexibility in treatment planning — a shorter radiation course can spare patients weeks of treatment without compromising survival, a meaningful quality-of-life consideration.
